Quantification of the Cannabinoid Type 1 Receptor Availability in the Mouse Brain

Overview

Journal Front Neuroanat

Date 2020 Dec 17

PMID 33328905

Citations 2

Authors

Isabelle Miederer

Viktoria Wiegand

Nicole Bausbacher

Petra Leukel

Stephan Maus

Manuela A Hoffmann

Beat Lutz

Mathias Schreckenberger

Affiliations

Soon will be listed here.

Abstract

: The endocannabinoid system is involved in several diseases such as addictive disorders, schizophrenia, post-traumatic stress disorder, and eating disorders. As often mice are used as the preferred animal model in translational research, in particular when using genetically modified mice, this study aimed to provide a systematic analysis of cannabinoid type 1 (CB1) receptor ligand-binding capacity using positron emission tomography (PET) using the ligand [F]MK-9470. We then compared the PET results with literature data from immunohistochemistry (IHC) to review the consistency between protein expression and ligand binding. : Six male C57BL/6J (6-9 weeks) mice were examined with the CB1 receptor ligand [F]MK-9470 and small animal PET. Different brain regions were evaluated using the parameter %ID/ml. The PET results of the [F]MK-9470 accumulation in the mouse brain were compared with immunohistochemical literature data. : The ligand [F]MK-9470 was taken up into the mouse brain within 5 min after injection and exhibited slow kinetics. It accumulated highly in most parts of the brain. PET and IHC classifications were consistent for most parts of the telencephalon, while brain regions of the diencephalon, mesencephalon, and rhombencephalon were rated higher with PET than IHC. : This preclinical [F]MK-9470 study demonstrated the radioligand's applicability for imaging the region-specific CB1 receptor availability in the healthy adult mouse brain and thus offers the potential to study CB1 receptor availability in pathological conditions.

Citing Articles

Chronic exposure to inhaled vaporized cannabis high in Δ9-THC alters brain structure in adult female mice.

Taylor A, Nweke A, Vincent V, Oke M, Kulkarni P, Ferris C Front Neurosci. 2023; 17:1139309.

PMID: 36950131 PMC: 10025305. DOI: 10.3389/fnins.2023.1139309.

Hippocampal expression of the cannabinoid receptor type 1 in canine epilepsy.

Kostic D, Nowakowska M, Freundt Revilla J, Attig F, Rohn K, Gualtieri F Sci Rep. 2023; 13(1):3138.

PMID: 36823232 PMC: 9950490. DOI: 10.1038/s41598-023-29868-3.

References

Terry G, Liow J, Chernet E, Zoghbi S, Phebus L, Felder C . Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage. 2008; 41(3):690-8. PMC: 2474463. DOI: 10.1016/j.neuroimage.2008.03.004. View

Casteels C, Vandeputte C, Rangarajan J, Dresselaers T, Riess O, Bormans G . Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease. Exp Neurol. 2011; 229(2):440-9. DOI: 10.1016/j.expneurol.2011.03.014. View

Wong D, Kuwabara H, Horti A, Raymont V, Brasic J, Guevara M . Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage. 2010; 52(4):1505-13. PMC: 6580862. DOI: 10.1016/j.neuroimage.2010.04.034. View

Ceccarini J, De Hert M, van Winkel R, Peuskens J, Bormans G, Kranaster L . Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage. 2013; 79:304-12. DOI: 10.1016/j.neuroimage.2013.04.052. View

Goffin K, Van Paesschen W, Van Laere K . In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain. 2011; 134(Pt 4):1033-40. DOI: 10.1093/brain/awq385. View

Miederer I, Maus S, Zwiener I, Podoprygorina G, Meshcheryakov D, Lutz B . Evaluation of cannabinoid type 1 receptor expression in the rat brain using [¹⁸F]MK-9470 microPET. Eur J Nucl Med Mol Imaging. 2013; 40(11):1739-47. DOI: 10.1007/s00259-013-2483-y. View

Gerard N, Pieters G, Goffin K, Bormans G, Van Laere K . Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry. 2011; 70(8):777-784. DOI: 10.1016/j.biopsych.2011.05.010. View

Neumeister A, Normandin M, Murrough J, Henry S, Bailey C, Luckenbaugh D . Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. Alcohol Clin Exp Res. 2012; 36(12):2104-9. PMC: 3418442. DOI: 10.1111/j.1530-0277.2012.01815.x. View

DSouza D, Cortes-Briones J, Ranganathan M, Thurnauer H, Creatura G, Surti T . Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016; 1(1):60-67. PMC: 4742341. DOI: 10.1016/j.bpsc.2015.09.008. View

10.

Ly H, Ceccarini J, Weltens N, Bormans G, Van Laere K, Tack J . Increased cerebral cannabinoid-1 receptor availability is a stable feature of functional dyspepsia: a [F]MK-9470 PET study. Psychother Psychosom. 2015; 84(3):149-58. DOI: 10.1159/000375454. View

11.

Busquets-Garcia A, Bains J, Marsicano G . CB Receptor Signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology. 2017; 43(1):4-20. PMC: 5719111. DOI: 10.1038/npp.2017.206. View

12.

Neumeister A, Normandin M, Pietrzak R, Piomelli D, Zheng M, Gujarro-Anton A . Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013; 18(9):1034-40. PMC: 3752332. DOI: 10.1038/mp.2013.61. View

13.

Pietrzak R, Huang Y, Corsi-Travali S, Zheng M, Lin S, Henry S . Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Neuropsychopharmacology. 2014; 39(11):2519-28. PMC: 4207337. DOI: 10.1038/npp.2014.110. View

14.

Takkinen J, Lopez-Picon F, Kirjavainen A, Pihlaja R, Snellman A, Ishizu T . [F]FMPEP-d PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease. Neurobiol Aging. 2018; 69:199-208. DOI: 10.1016/j.neurobiolaging.2018.05.013. View

15.

Casteels C, Koole M, Celen S, Bormans G, Van Laere K . Preclinical evaluation and quantification of [¹⁸F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain. Eur J Nucl Med Mol Imaging. 2012; 39(9):1467-77. DOI: 10.1007/s00259-012-2163-3. View

16.

Breivogel C, Sim L, Childers S . Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther. 1997; 282(3):1632-42. View

17.

Steindel F, Lerner R, Haring M, Ruehle S, Marsicano G, Lutz B . Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus. J Neurochem. 2013; 124(6):795-807. DOI: 10.1111/jnc.12137. View

18.

Ceccarini J, Casteels C, Koole M, Bormans G, Van Laere K . Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. Eur J Nucl Med Mol Imaging. 2013; 40(10):1582-94. DOI: 10.1007/s00259-013-2456-1. View

19.

Lahesmaa M, Eriksson O, Gnad T, Oikonen V, Bucci M, Hirvonen J . Cannabinoid Type 1 Receptors Are Upregulated During Acute Activation of Brown Adipose Tissue. Diabetes. 2018; 67(7):1226-1236. DOI: 10.2337/db17-1366. View

20.

Mirrione M, Schiffer W, Fowler J, Alexoff D, Dewey S, Tsirka S . A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage. 2007; 38(1):34-42. PMC: 2084071. DOI: 10.1016/j.neuroimage.2007.06.032. View